Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
Ñompany Maksim-LLC. Ýëåêòðîïðèâîäû. Made and sell.
Popular Articles

Bronx Campaign Boosts HIV Testing; Fauci Issues Statement Regarding National Testing Day
A three-year initiative launched last year by the New York City Department of Health and Mental Hygiene to test every adult in the Bronx for HIV has boosted testing by 28 percent, according to city health officials, the New York Times" blog "City Room" reports. The "Bronx Knows" campaign began with an effort to make voluntary HIV testing routine in emergency departments and clinics, where city officials said, "cumbersome consent procedures required by state law have deterred doctors from offering the tests," according to "City Room" (Chan, "City Room," New York Times, 6/24). The initiative - which involves clinics, hospitals and community organizations - tested nearly 160,000 Bronx residents in the past 12 months (United Press International, 6/24). The city also is participating in National HIV Testing Day on Saturday ("City Room," New York Times, 6/24).
new payday loan lenders
Phase III Study Showed Lucentis Improved Vision In Patients With Branch Retinal Vein Occlusion
Genentech, Inc. announced today that the Phase III study BRAVO showed Lucentis® (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to branch retinal vein occlusion. The safety profile of Lucentis was consistent with previous experience and no new adverse events related to Lucentis were observed in the study. Retinal vein occlusion (RVO) is a common cause of vision loss that occurs when blood flow through a retinal vein becomes blocked, such as by a blood clot.
News of the day
More Than Half Of Texas Physicians Do Not Always Recommend HPV Vaccine To Girls
The Advisory Committee on Immunization Practices recommends the human papillomavirus vaccination for all 11- and 12-year-old girls, but results of a recent survey showed that more than half of Texas physicians do not follow these recommendations.
Health Insurance

TRP Ion Channel Drug Can Treat Allergy-Induced Asthma In Mouse Study

Hydra Biosciences, Inc., a biotech company developing novel ion channel drugs, has announced that research published by Hydra Biosciences scientists and collaborators at Yale University for the first time identified the ion channel TRPA1 as playing an essential role in allergic asthma and demonstrated that Hydra"s TRPA1 antagonist HC-030031 effectively treated allergic asthma in mice. The paper, titled "A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma," will appear this week in Proceedings of the National Academy of Sciences (PNAS). "This study demonstrates - for the first time - that TRPA1 plays a key role in asthma," said Sven-Eric Jordt, Ph.D, of Yale University, the paper"s lead author and a member of the Hydra Biosciences Scientific Advisory Board. "These data have extraordinary implications for treating asthma, and a number of other inflammatory conditions, in a completely new way, as we believe that blocking TRPA1 may prevent the infiltration of the lung by the inflammatory cells responsible for asthma symptoms such as wheezing and mucus overproduction." This breakthrough research could open a completely new avenue of drug treatment for asthma. There has been a dramatic increase in the number of asthma cases reported in recent decades. Scientists know that asthma involves an immune response to inhaled allergens that results in inflammation, mucus secretion and bronchial constriction. But the limited efficacies of therapies aimed at the immune system suggest that additional physiological mechanisms may be involved in asthmatic inflammation. Targeting the TRPA1 ion channel could represent a therapeutic breakthrough in the treatment of allergic asthma. Hydra Biosciences, a leader in the field of TRP drug discovery, is currently developing a novel TRPA1 inhibitor and is advancing this drug candidate into human clinical trials within 12 months. In the study, the research team evaluated the ability of a TRPA1 antagonist to inhibit TRPA1 function in a murine model of asthma. The antagonist successfully alleviated inflammation, airway constriction, and mucus overproduction associated with allergic asthma. Genetic deletion of TRPA1 in mice elicited similar effects, confirming the central role of TRPA1 in asthma. "The finding that TRPA1 plays an essential role in allergic asthma is revolutionary, and suggests that a drug candidate that successfully modulates this ion channel has the potential to treat asthma and other allergic inflammatory conditions," said Russell Herndon, Chief Executive Officer, Hydra. "Due to our experience and expertise with TRP ion channels, Hydra is on the leading edge in this field, and we are aggressively advancing a TRPA1 drug candidate into clinical studies within 12 months." Kathryn Morris Yates Public Relations


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009